Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secretary Joseph K. Belanoff - Co-Founder, President, CEO & Director Roberto W.
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.32 per share a year ago.
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators
Applications of Relacorilant and Corcept's other cortisol modulators are not being valued by investors. Results from the Rosella clinical trials showcase the multifaceted applications of cortisol modulators for rare diseases. Korlym's steady revenue growth can support Corcept's increased R&D for the foreseeable future.
Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring
Corcept Therapeutics remains a strong buy, with recent stock weakness attributed to put options trading rather than fundamental issues. Management maintains aggressive 2025 and long-term revenue guidance, supported by increased testing, salesforce expansion, and a backlog of prescriptions. The company is submitting a New Drug Application for Relacorilant in ovarian cancer, opening a new oncology revenue stream beyond endocrinology.
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025.
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by.
Corcept Therapeutics (CORT) Meets Q1 Earnings Estimates
Corcept Therapeutics (CORT) came out with quarterly earnings of $0.17 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.25 per share a year ago.
Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss
Despite a Q4 revenue miss, Corcept's 2025 revenue still grew 40% to $675 million, and management provided strong guidance for 2025 and beyond, projecting up to $5 billion in revenue. Corcept's potential patient population has expanded significantly from 10,000 to over 1 million in the past year, and has promising drugs in the pipeline, making it a strong acquisition target. The company announced positive trial results for an ovarian cancer medication, opening an entirely new revenue stream.
It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder
Corcept is transitioning from a single-product company to a multi-product, multi-market Platform Growth™ company, promising rapid revenue and earnings growth. Relacorilant's success in platinum-resistant ovarian cancer and potential FDA approval for hypercortisolism could significantly boost Corcept's market presence and revenue. Corcept's expanding pipeline includes promising treatments for prostate cancer, ALS, MASH, and resistant hypertension, diversifying its product portfolio and reducing investor risk.
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
